Latest Market Access News

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

Sprintex Limited has advanced its commercial and technological milestones with major European and Indian orders, breakthrough energy efficiency validation, and a successful A$3.25 million equity raise, positioning the company for accelerated growth.

Mineral Resources Limited reported a steady Q3 FY25 with operational progress at Onslow Iron and lithium assets, alongside ongoing corporate governance reforms and robust financial health.

Adriatic Metals has completed a two-tranche institutional placement raising A$80 million to fast-track its Vares Processing Plant expansion and support production growth at Rupice Mine.

Australian Bond Exchange Holdings has entered a strategic Liquidity Provision Agreement with ViewTrade Australia, aiming to broaden investor access to OTC securities globally through integrated technology and expanded market channels.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

St George Mining has forged a strategic partnership with global EPC leader Xinhai, securing an A$8 million investment and a pathway to fast-track the Araxá niobium-REE project in Brazil.

Trigg Minerals has secured a dual listing on the U.S. OTCQB market, enhancing accessibility for American investors and positioning itself for critical funding opportunities.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Carnaby Resources has completed the settlement of Tranche 2 of its recent share placement, issuing 13.5 million new shares to raise approximately $4.2 million, including participation from its board members.